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between HFS and overall and disease-free survival in two randomised controlled trials
(RCTs) where capecitabine was administered to stage II and stage III colorectal cancer
patients.
Methods: The maximum grade of HFS (CTCAE graded) experienced during treatment,
overall survival and disease-free survival was available from 927 patients from the
QUASAR 2 trial (3) and 526 patients from the SCOT trial (4) who had been treated
with capecitabine either as a single agent or in combination with either bevacizumab or
oxaliplatin. QUASAR 2 patients received 1250 mg/m2 capecitabine twice daily for 14
days and SCOT patients received 1000 mg/m2 capecitabine twice daily for 14
days. Grade 2þHFS was experienced by 513 patients in QUASAR 2 and 78 patients in
SCOT. The association between HFS and overall and disease-free survival was investi-
gated in each study using a multivariate Cox-proportional hazards model including
tumour site, stage, sex and age as covariates. Duration of treatment was included as an
additional covariate in the SCOT trial where patients were randomised to receive 12
weeks or 24 weeks of treatment.
Results: Mean follow-up of patients in from QUASAR 2 and SCOT was 4.48 years and
4.78 years respectively. Of the patients, 55.3% from the QUASAR 2 trial experienced
grade 2 HFS and 14.82% of patients from the XELOX arm of SCOT trial experienced
grade 2 HFS. QUASAR 2 patients who experienced grade 2þHFS had an increase in
overall survival compared to those who experienced no HFS or only grade 1 events (HR
0.61; 95% CI 0.45-0.83, P¼ .0017). A similar result was observed for disease-free sur-
vival (P¼ .03). HFS was far less common in the SCOT trial but data from the patients
treated with capecitabine and oxaliplatin supported the findings in QUASAR 2. For
overall survival, the HR was 0.74 (95%CI, 0.39-1.4; P¼ .36) and 0.75 (95% CI, 0.46-
1.23; P¼ .258) for disease-free survival. In a fixed effects meta-analysis of the two trials
the HR for overall survival was 0.63 (95% CI, 0.48-0.84; P¼ .01) and for disease-free
survival 0.75 (95% CI, 0.58-0.98; P¼ .04).
Conclusion: Dose reductions and delays as a result of HFS do not negatively impact
upon survival. Data from two RCTs in the colorectal cancer setting supports HFS as a
biomarker of improved survival. This finding will be explored in other studies that are
part of the IDEA consortium. References: 1. Ogawa et al. Oncology. 2017;(93 Suppl
1):113-119. 2. Bailey et al. J Oncol Pharm Pract. 2018(3):190-197. 3. Kerr et al. Lancet
Oncol. 2016(11):1543-1557. 4. Iveson et al. Lancet Oncol. 2018(4):562-578.
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Introduction: The anti-angiogenic fusion protein aflibercept (AFL) targeting VEGF-A,
VEGF-B and PlGF has shown significantly prolonged overall survival of patients with
metastatic colorectal cancer (mCRC) when administered in combination with
FOLFIRI. In combination with FOLFIRI, it is approved for the treatment of mCRC that
is resistant to or has progressed after oxaliplatin-containing therapy.
Methods: QoLiTrap (AIO-LQ-0113) is a multinational (DACH), ongoing, non-inter-
ventional study of 1500 patients to primarily evaluate the Quality-of-life (QoL) in
mCRC patients treated with AFLþFOLFIRI using the EORTC-QLQ C30 questionnaire
at baseline and before every cycle.
Results: For this interim analysis (data cut-off: January 2, 2019), 839 patients (mean
age: 64.7 6 9.8 years; 64.4% male, 50.9% with documented RAS mutation, ECOG 0-1:
86.0%) who completed the baseline and at least 2 post-baseline EORTC-QLQ C30
questionnaires were evaluated. AFL was administered for a median of 7 cycles (range:
1-65). In total, 92.0% of patients received prior palliative therapy or prior therapy dur-
ing metastatic stage. Of those patients, 56.7 % were pretreated with bevacizumab,
15.3% with anti-EGFR antibodies (cetuximab and/or panitumumab) and 14.6 % with
both. Mainly, the study treatment was given as 2nd-line treatment (49.3%), followed
by 3rd (22.9%) and 4th-line (11.3%) treatment. Median global health score at baseline
was 58.3 and decreased moderately (mean change -3.4%, P< 0.0001) within the first 12
weeks of therapy. There was a greater reduction in patients with RAS mutation (mean
change -5.1%) compared to RAS wild-type (mean change -1.1%). Evaluable patients
(n¼ 406/839) pretreated with anti-EGFR and/or bevacizumab over all therapy lines
had 20.0% complete response (CR)þ partial response (PR) and 52.5% stable disease
(SD) as best response to AFL. Evaluable patients receiving 2nd (n¼ 208/839) and 3rd-
line (n¼ 102/839) study treatment reached 25.0% CRþ PR and 49.5% SD, and 16.7%
CRþ PR and 56.9% SD, respectively. Median PFS of patients during 2nd-line therapy
pretreated with anti-EGFR or bevacizumab was 7.6 months (95% CI, 6.2-30.1) and 8.3
months (95% CI, 6.9-9.1), respectively. Patients in 3rd-line with pretreatment of anti-
EGFR, bevacizumab, or both reached a median PFS of 9.4 months (95% CI, 3.2-12.5),
6.8 months (95% CI, 4.5-9.9), and 7.8 months (95% CI, 4.9-10.6), respectively.
Summarily, patients pretreated with any biological prior to AFL therapy independent
of therapy line had a median PFS of 7.1 months (95% CI, 6.3-8.1). Toxicity was in line
with the known safety profile of the study medications. The most common adverse
events (occurring in> 10% of patients) were non-serious (83.6% of AEs) and included
diarrhea, oral mucositis, fatigue, nausea, and hypertension, predominantly of mild-to-
moderate nature (CTCAE grade 2).
Conclusion: This current interim analysis showed encouraging efficacy results for
mCRC patients treated with AFLþFOLFIRI under routine conditions, including
patients with prior anti-EGFR antibody and/or bevacizumab therapy. Patients on 2nd-
line treatment benefited most. Global health status declined moderately without clini-
cal relevance during the study treatment. This study was supported by Sanofi-Aventis
Deutschland GmbH.
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Introduction: Retrospective analyses and phase 2 studies suggest that administering an
anti-EGFR in advanced lines may be effective in mCRC pts who achieved benefit from a
1st-line anti-EGFR containing regimen. The identification of clinical features associ-
ated with benefit from anti-EGFR re-treatment (re-tx) in pts experiencing PD during
1st-line anti-EGFR (rechallenge) or after its interruption (reintroduction), is a major
clinical need.
Methods: A real-life data-base including a total of 5530 pts treated at 6 institutions
from December 2010 to October 2018 was queried. Pts retreated with anti-EGFRs,
with RAS/BRAF wild-type status on tissue samples, who had received a 1st-line anti-
EGFR-based tx with at least SD as best response, and at least one further line of therapy
before anti-EGFR re-tx, were included. The association with RECIST response (RR),
PFS and OS was investigated for the following variables: RR (PR or CR vs SD) and PFS
during 1st-line; time from the last anti-EGFR administration to 1st-line PD (i.e. re-
introduction vs rechallenge); reason for anti-EGFR discontinuation in 1st-line (PD vs.
other); number of anti-EGFR-free lines of therapy before re-tx; anti-EGFR free interval
(time between the last anti-EGFR administration in 1st-line and the time of re-tx); pri-
mary tumor side; time from the diagnosis of metastatic disease to re-tx ( vs.< 18
mos).
Results: Data from 86 pts were retrieved. In total, 56 (65%) and 30 (35%) received
anti-EGFR rechallenge or reintroduction, respectively. Median anti-EGFR free interval
was 15.1 mos. The RR during re-tx was 19.8%, with a DCR of 46.5%. Median PFS and
OS were 3.6 and 10.2 mos, respectively. No significant association of investigated fea-
tures with RR and PFS was observed. No differences in RR or PFS were observed among
pts receiving anti-EGFR re-tx as rechallenge or reintroduction (20.4% vs 23.1%, P¼.99;
median PFS: 3.49 vs 4.97 mos; P¼.61). Patients with left-sided tumors had longer OS
(HR 0.50; 95% CI, 0.26-0.93; P¼.005).
Conclusion: Clinical factors that are generally believed to affect the efficacy of anti-
EGFR re-tx are not confirmed in our series. Therefore, clinicians should not rely on
those characteristics in their decision-making on anti-EGFR re-tx, and adequate studies
for implementing liquid biopsy in clinical practice are urgently needed.
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